A clinical-stage biopharmaceutical company on a mission to introduce a first-in-class antipsychotic for patients in the U.S. with neuropsychiatric conditions.
Joined January 2020
- Tweets 116
- Following 43
- Followers 84
- Likes 8
63 Photos and videos
We recently gathered as a team in New York. The opportunity to connect in person strengthened collaboration across our teams and reinforced the shared commitment behind the work we do advancing novel therapies for neuropsychiatric disorders. Learn more: bit.ly/4pMbHcR
1
1
71
May 28
We will participate in two upcoming investor conferences, where we’ll join industry leaders, investors, and peers to discuss our work advancing LB-102 as a potential new treatment for neuropsychiatric disorders. Details below and in our press release: bit.ly/4aixZh1
66
May 21
Next up in our #LBBold series: Kathy Dorsey, Senior Director, Clinical Operations, who helps drive our clinical programs. To Kathy, being bold means acknowledging challenges and choosing to approach them as opportunities to learn and grow. Learn more: bit.ly/44IAYwv
76
May 20
Our trials would not be possible without the patients, carepartners, and healthcare professionals who participate. On #ClinicalTrialsDay, we thank them for their commitment to advancing neuropsychiatric research. Learn more about #CTD2026: bit.ly/3evClE1
1
54
May 19
Don’t miss us at #ASCP2026, as we’ll be engaging with key opinion leaders and peers in neuropsyciatric drug development. Our team is looking forward to connecting with the community and contributing to discussions on advancing innovative therapies for neuropsychiatric conditions.
44
We are proud to mark #MentalHealthMonth as part of a community working towards #MoreGoodDaysTogether and reflection on what supports mental well being. Learn more from @MentalHealthAm’s #MHM action guide: bit.ly/4cPxGMy
2
57
Apr 29
Our CEO, Heather Turner, will participate in a panel at the Convergence Forum alongside fellow industry leaders discussing their past experiences navigating bold biotech exits. Learn more about the event: bit.ly/485jSe7
53
Apr 22
We are pleased to share that the results from NOVA-1, the Phase 2 trial which evaluated our investigational treatment LB-102 in #schizophrenia, are now published in @JAMAPsych. Read more: bit.ly/4sN4Z7q
78
Mar 31
Next up in our #LBBold series: Rezi Zawadzki, VP, Biometrics, who drives data-informed decisions across our programs. Motivated by the need for better mental health solutions, Rezi brings purpose to advancing LB-102. Learn more about our team: lbpharma.us/about-us/
71
Mar 27
At #SIRS2026, we shared data from NOVA-1, the Phase 2 trial for our investigational therapy LB-102 in #Schizophrenia that underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia. Read more: bit.ly/4t9S4gx $LBRX
1
145
Mar 25
We have initiated NOVA-2, a pivotal Phase 3 trial of LB-102, once-daily, oral investigational small molecule being advanced as a potential first benzamide in the U.S. for the treatment of #Schizophrenia & other neuropsychiatric disorders. Learn more: bit.ly/47prSWR $LBRX
2
2
441
Mar 23
We’re looking forward to hosting a satellite symposium at the 2026 Annual Congress of @SIRSGlobal (#SIRS2026). Learn more about the conference: bit.ly/4d5C36C
66
Excited to announce that Robert Lenz, M.D., Ph.D., has joined our Board of Directors. His neuroscience R&D leadership will help guide the clinical advancement of LB-102 in #Schizophrenia, #BipolarDepression & adjunctive #MajorDepressiveDisorder. More here: bit.ly/4cxGtD5
87
Members of our leadership team will participate in the following investor events in March:
💡 Investival Showcase USA on March 10
🤝 Leerink Partners Global Healthcare Conference on March 11
🧠 Stifel 2026 Virtual CNS Forum on March 17
Details here: bit.ly/40IzVKv $LBRX
105
Feb 11
On International Day of Women and Girls in Science, we recognize the women of LB Pharma who represent 65% of our team and advance science with inclusive leadership and diverse perspectives. Learn more about #IDWGIS: bit.ly/4hKylyA
#WomenInScience #EveryVoiceinScience
96
With new funding secured, we intend to explore the potential of our investigational oral small molecule LB-102 as an adjunctive treatment for major depressive disorder in a Phase 2 trial. Learn more: bit.ly/4tBj7CL $LBRX
1
655
Jan 28
Bipolar disorder affects an estimated 2.8% of Americans and remains a significant burden. We are advancing LB-102, an investigational therapy for #BipolarDepression, in a recently initiated Phase 2 trial. Learn more: bit.ly/4qcV0bg
1
128
Jan 27
Bold innovation requires purpose-driven people. In our new #LBBold series, we'll highlight the talented minds behind LB Pharma. Our Senior Director of Corporate Administration, Lauren Stipp, plays an important role in our success. Learn about our team: bit.ly/44IAYwv
1
1
122
Jan 26
We have initiated ILLUMINATE-1, a Phase 2 trial evaluating our investigational oral small molecule, LB-102, in #BipolarDepression. This is an important step in advancing the development program for LB-102 to include mood disorders. Read more: bit.ly/4662RPN $LBRX
164